ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Macrophage Extracellular Traps in Immunity and Cancer.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Endothelial Senescence-Associated Secretory Signaling Promotes Macrophage Extracellular Traps Formation and Contributes to the Exacerbation of Combined Lung Injury.International journal of biological sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Macrophage extracellular Traps (METs) are web-like structures released by activated macrophages, composed of a DNA backbone decorated with various proteins. Their core function lies in entrapping and restricting pathogen dissemination, representing an important innate immune defense mechanism of macrophages. Through the activation of multiple inflammatory factors and protein components, METs amplify the inflammatory cascade and are detected in various inflammatory conditions. Moreover, recognizing chronic inflammation as a major oncogenic driver, the role of METs in cancer is increasingly appreciated. By fostering an immunosuppressive tumor microenvironment and degrading the extracellular matrix, METs facilitate epithelial-mesenchymal transition, thereby promoting angiogenesis and tumor cell survival. In addition, METs affect the efficacy of cancer immunotherapy. While METs antagonize cancer immunotherapy by creating a physical barrier and fostering immunosuppression, their intrinsic cytotoxicity and ability to amplify inflammatory signals also synergize with immune-activating strategies. This review comprehensively examines the underlying function of METs in immunity, tumorigenesis, and cancer immunotherapy. Deciphering these functional connections will provide critical insights for targeting METs to enhance the efficacy of cancer immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.